Cytokinetics Inc (NAS:CYTK)
$ 48.98 -10.25 (-17.31%) Market Cap: 5.14 Bil Enterprise Value: 6.35 Bil PE Ratio: 0 PB Ratio: 0 GF Score: 43/100

Q3 2021 Cytokinetics Inc Earnings Call Transcript

Nov 03, 2021 / 08:30PM GMT
Release Date Price: $36.67 (+5.74%)
Operator

Good afternoon, and welcome, ladies and gentlemen, to Cytokinetics' Third Quarter 2021 Conference Call. At this time, I would like to inform you that this call is being recorded. (Operator Instructions)

I will now turn the call over to Joanna Siegall, Cytokinetics' Senior Manager of Corporate Communications and Investor Relations. Please go ahead.

Joanna Siegall

Good afternoon, and thanks for joining us on the call today. Robert Blum, our President and Chief Executive Officer, will begin with an overview of the quarter and recent developments; then Fady Malik, our EVP of Research and Development, will provide an update on omecamtiv mecarbil, including recently presented additional analyses for GALACTIC-HF, as well as an update on our ongoing next steps with the FDA.

Next, Stuart Kupfer, our SVP and Chief Medical Officer, will provide an update on our development program for aficamten by recapping the results from Cohorts 1 and 2 of REDWOOD-HCM, elaborating on continuing activities in REDWOOD-HCM and reviewing the design of SEQUOIA-HCM, our planned

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot